Efficacy of Angiolite Stent vs a Second-generation Drug-eluting Stent Xience for Percutaneous Coronary Intervention

Randomized Clinical Trial to Compare the Efficacy of Angiolite Stent Versus a Second-generation Drug-eluting Stent Such as Xience in Patients With Indication of Percutaneous Coronary Intervention

Clinical trial with an "European Community marked" medical device in patients with ischemic heart disease and clinical indication of coronary revascularization with drug-eluting stent.

Clinical follow-up will be done according to this way: first month telephone or face-to-face interview and at 6 ± 1 month an Angiography follow up + OCT (optical coherence tomography)

A randomized clinical trial to compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.(non-inferiority design)

Inclusion Criteria:

• Patients with clinical or subclinical ischemic heart disease with indication of percutaneous revascularization.
• "De Novo" lesions ≥ 70%
• Reference diameters ≥ 2 mm and ≤ 4 mm Accepted participation in the registration with the signing of informed consent

Exclusion Criteria:

• Cardiogenic shock
• Pregnancy
• Intolerance or allergy to anti platelet or anticoagulant therapy
• Elective surgical procedure scheduled within 6 months after inclusion in the study
• Expectancy of life of less than 1 year.
• Impossibility of doing 1 year clinical follow-up.
• Primary angioplasty in patients with killip class III-IV or mechanical complications.
• Patient with pre-procedure restenosis.
• Patients who will not be treated all lesions with the Angiolite stent.
• Total occlusions
• Truncus disease